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Abstract
Background: Sheeppox (SPP) is one of the priorities, high-impact animal diseases in many developing countries,
where live attenuated vaccines are routinely used against sheeppox virus (SPPV). In an event of an SPP outbreak,
historically disease-free countries would hesitate to use of live vaccines against SPPVdue to the safety and trade
reasons. Currently no killed SPPV vaccines are commercially available. In this study, we developed an inactivated
Romanian SPPVvaccine and assessed its efficacy and potency in comparison with a live attenuated Romanian SPPV
vaccine. Four naïve sheep were vaccinated once with the Romanian SPPV live attenuated vaccine and16 sheep were
vaccinated twice with the inactivated vaccine. All sheep in the live vaccine group were included in the challenge trial,
which was conducted using a highly virulent Moroccan SPPV field strain. Eight sheep of the inactivated vaccine group
were challenged and the remaining sheep were monitored for seroconversion. Experimental animals were closely
monitored for the appearance of clinical signs, body temperature and inflammation at the injection site. Two naïve
sheep were used as unvaccinated controls.
Results: The inactivated Romanian SPPV vaccine was found to be safe and confer a good protection, similar to the live
vaccine. Specific antibodies appeared from seven days post vaccination and remained up to nine months.
Conclusion: This study showed that the developed inactivated Romanian SPPV vaccine has a potential to replace
attenuated vaccine to control and prevent sheep pox in disease-free or endemic countries.
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Background
Sheeppox virus (SPPV), the etiological agent of sheeppox
(SPP), is a member of the genus Capripoxvirus within
the family Poxviridae. SPP is a transboundary disease
which is notifiable to the World Organization of Animal
Health (OIE) [1]. The disease can be mild in indigenous
sheep breeds, but usually causes severe or fatal infection
in newly introduced, fully susceptible animals. In naïve
animals, morbidity and mortality may be as high as
100 % [2]. SPPV affects all ages of sheep but the clinical
signs are more severe in young lambs [3]. The disease is
characterized by fever, generalized papules or nodules in
the skin, respiratory distress, pox lesions in the respira-
tory and gastrointestinal tracts, and sometimes death.
SPP is endemic in Central and North Africa, the Middle
East, Central Asia and the Indian subcontinent.
Recently, SPP has also reached southern Europe [4].
In endemic countries, vaccination is considered the
only economically feasible way to control the disease
and improve small ruminant productivity. Numerous
live vaccines have been developed and worldwide used,
while inactivated vaccines are considered less effective
and have only been tested at the laboratory level [5].
Despite the high efficacy of live vaccines, SPP is still
endemic in those regions where vaccination is routinely
practiced. In North Africa where SPPV has a strict sheep
tropism, after decades of vaccination using a live attenu-
ated vaccine, SPP is still causing significant economic
losses for sheep farming industry [6]. In Greece, SPP re-
occurred in 2013 and in 2015 the outbreak is still
continuing, despite extensive stamping-out of infected
and in-contact animals, movement restrictions and other
supportive control and eradication measures (OIE
Wahid database). The use of SPPV live vaccine is not
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permitted within the European Union (EU) member
states. However, in a situation like in Greece, a safe non-
replicating, effective and cheap inactivated emergency
vaccine could provide a more efficient tool to limit the
spread of the disease without a need for culling a large
number of animals which is expensive and highly stress-
ful for the farmers, destroying decades of work for the
genetic improvement of a flock.
According to current OIE trade recommendations and
EU directive (90/425/EEC of 26 June 1990), both SPP
outbreak and use of any SPPV vaccines would inflict im-
mediate restrictions to the export of live animals and
their products from affected to disease-free countries. In
addition, three years after the last SPP case or last vac-
cination, are required to re-gain the disease-free status.
The lack of DIVA component in currently available vac-
cines would hamper the retrospective serological sur-
veys, although it is unlikely that the antibody levels in
vaccinated animals would remain on the detectable level
for three years.
In another hand, it has been reported that some atten-
uated live vaccines induced severe pock reactions at the
injection site or even mild disease in vaccinated animals
[7]. Poor quality live vaccines (low vaccine titre) may
also serve as vehicles for extraneous virus contaminants
such as Border Disease virus (BDV). In the past, out-
break of BDV occurred inTunisia after vaccination by a
BDVcontaminated SPPV vaccine and in France abovine
viral diarrhea (BVD) contaminated Aujeszky disease live
vaccine [8, 9]. In addition, theoretically there is a possi-
bility that an attenuated vaccine virus could revert back
to virulent, although such an occurrence has never been
reported in SPPV vaccines.
Thus, an inactivated SPPV vaccine would provide a safe
and valuable tool to protect livestock against SPPV, par-
ticularly during the first incursion of the virus in the previ-
ously disease-free country. In this study, we developed an
inactivated vaccine against SPPV and tested its efficacy
and potency by serology and challenge experiment in
comparison with a live attenuated SPPV vaccine.
Methods
Vaccine preparation
The SPPV Romanian strain was propagated on Vero
cells [10] and maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) with 10 % irradiated fetal
calf serum. The inoculation was carried out using an
M.O.I (Multiplicity of Infection) of 0.01.
The live vaccine was prepared from the virus suspen-
sion by the addition of stabilizer (4 % peptone, 8 %
sucrose and 2 % glutamate) followed by lyophilization.
The inactivated vaccine was prepared from the same
virus suspension by inactivating the virus with β-
propiolactone. The complete inactivation of the vaccine
virus and sterility of the product was confirmed before
vaccine formulation. The aluminum hydroxide adjuvant
was added at 2.1 mg/ml. The final product was distrib-
uted in 50 ml vials and stored at 4 °C before use.
Sheep vaccination
Eighteen healthy sheep, six to eight months of age,
representing the Timehdit breed of the Atlas mountains,
were tested SPPV seronegative by virus neutralization
(VN) test. Group 1 (G1) comprised 16 sheep which were
vaccinated subcutaneously in the groin area with a vol-
ume of 2 ml of the inactivated SPPV vaccine represent-
ing a dose of 105.5 TCID50. Two sheep were kept as
unvaccinated controls. Group 2 (G2) comprised four
animals which were vaccinated with 0.5 ml of the live
attenuated vaccine, representing a dose of 103.0 TCID50.
All immunized animals were daily monitored for 14 days
for rise in body temperature, appearance of clinical signs
typical for SPP and inflammation at the injection site.
Animals in G1, received a booster vaccination at D21 in
the same conditions. Serum samples were collected from
the vaccinated sheep weekly until 2 months, then at one
month interval for the remaining unchallenged eight
sheep up to 9 months.
Experimental challenge infection
Vaccine potency testing was carried out by a challenge
trial, using a virulent field SPPV strain (Hd2012) at the
BSL3 laboratory. In the inactivated vaccine group G1,
eight sheep out of 16 were challenged on D35 and in live
vaccine group G2 four sheep were challenged on D28
after vaccination. Two naïve sheep were challenged as
unvaccinated controls.
The challenge was conducted using a local Moroccan
highly virulent SPPV field strain. The virus was adminis-
tered by intra-dermal (ID) route in the flank of the ani-
mals at ten fold dilutions (10-1 to 10-6) to perform a virus
titration comparatively on vaccinated and control animals.
Sheep were monitored daily for clinical signs, rectal
temperature and the development of inflammation in
each of the injection site. The presence of any inflamma-
tion was considered positive for the virus titration. The
average virus titres of G1 and G2 were compared with
the titre obtained in the unvaccinated animals and the
difference between the two titres, expressed in log10,
represented the protection index [11].
Serological response
Serum samples were tested for the development of
specific SPPV antibodies using VN test as described in
the OIE Terrestrial Manual (OIE Chapters 2.7.11 and
2.7.14). This test is based on a serial ¼ dilutions of heat
inactivated sera and a set amount of infectious virus
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(100 TCID50). The neutralizing antibody titer was calcu-
lated in accordance to Reed and Muench method [12].
Statistical analyses
Differences between antibody titers obtained with live and
inactivated vaccines, and between virus titers in vaccinated
and unvaccinated animals, were determined using a one-
way analysis of variance (ANOVA) followed by a student
t-test. Values of P ≤0.05 were considered significant.
Results
Sheep vaccination
Three weeks following vaccination, the body temperature
of vaccinated sheep in G1 remained within normal limits
and no clinical signs typical for SPP were observed. At the
vaccination site, transitory inflammation 1 cm to 2 cm in
diameter was observed in some animals, disappearing in
few days. In G2, slight increase in body temperature was
observed six to eight days after vaccination and in some
animals a local reaction was observed atthe vaccination
site, persisting in some cases up to 20 days.
In G1, anti SPPV antibodies appeared as early as D7
post-vaccination. Compared to live vaccine, they registered
similar values at D14 and D21, but reached a significantly
higher value of antibody neutralizing titer (2.1 log10) on
D28 (P ≤0.05). In G2, the rise of anti SPPV antibodies was
noted later on D14 post-vaccination, and showed a slight
decrease on D28 to reach a value of 1 log10 (Fig. 1).
Most vaccinated sheep in G1showed an increase of
antibody titre following the booster. In eight unchal-
lenged vaccinated sheep, the immunity persisted for at
least 9 months. The antibody neutralizing titre seemed
to stabilize at 1 to 2.1 log10 (Fig. 2).
Experimental infection
On the challenge, the two unvaccinated control animals
exhibited a rise in body temperature between D4 and
D11 (Fig. 3). Local reactions at the injection sites were
observed from D3, increasing in size the following days.
Typical SPPV skin nodules (not associated with injection
sites) appeared between D10 and D11 (Fig. 4). The ob-
tained virus titres on the flank of the two unvaccinated
control animals were 5.5 log10 ID50/ml and 5.9 log10
ID50/ml, significantly higher than that obtained with
vaccinated animals (P ≤ 0.05) (Table 1).
After the challenge, the vaccinated sheep of G1 and
G2 showed a transient two days increase in temperature
between 39.6 °C and 39.7 °C at D6 and D7(Fig. 3) and a
hypersensitivity reaction at the injection site two days
after the challenge, generally in the first dilutions.
None of the immunized animals showed clinical sign-
sof SPP during the observation period. Inflammations
due to the virus replication were observed in dilutions
10-1 and 10-2 between D4 and D12. There was no signifi-
cant difference in the titer and the protection index be-
tween G1 and G2 (P ≥ 0.05). The obtained infectious
titre was 1.4 log10 ID50/ml for the inactivated vaccine
G1 and 0.75 log10 ID50/ml for the live vaccine G2
(Table 1). The protection index was estimated to 4 for
G1 and 4.6 for G2.
Fig. 1 Neutralizing SPPV antibody titers after sheep vaccination. The
results correspond to the mean antibody titers ± SEM of 16 sheep
vaccinated with the inactivated Romanian SPPV vaccine strain (G1) and 4
sheep vaccinated with the live attenuated Romanian SPPV vaccine (G2).
(a–b) indicate a significant difference in means antibody titers between
animals of G1 and G2 at the 0.05 level
Fig. 2 Neutralizing SPPV antibody titers after vaccination of sheep with the inactivated Romanian SPPV vaccine strain. The results correspond to
the mean of antibody titer of eight vaccinated sheep ± SEM
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All vaccinated animals of G1 and G2 showed ananti-
body response that increased after the challenge.
Discussion
In endemic countries a variety of attenuated live vaccines
have been used against SPPV. Live attenuated vaccine pro-
tection is mediated by both cellular and humoral immun-
ity. While, inactivated vaccines are believed to be less
effective in stimulating the cell mediated immune
response, which is the predominant protective response to
poxvirus infection. In addition, in vaccinated sheep a poor
correlation between antibody levels and immune status of
animals has been reported [5], suggesting that live repli-
cating vaccines are required for the development of effect-
ive immunity against pox disease [13, 14].
Nevertheless, in many countries, live vaccines use was
banished because of its potential to induce mild diseases
in animals and the risk of contamination by extraneous
pathogens. The use of inactivated vaccines would be,
thus, an alternative to protect livestock against pox dis-
eases. In the present study, an inactivated and live atten-
uated SPPV vaccines, were compared in terms of their
safety and potency. Romanian strain has been selected
for vaccine preparation because it proved to be effective
for protection against SPP infection [10, 15].
Sheep were observed for three weeks following
immunization. The inactivated vaccine was safe to use,
as all vaccinated animals remained healthy, no increase
in body temperature after vaccination was detected and
only a small inflammation at the injection site was ob-
served. A serological response was detected one week
earlier for the inactivated vaccine group than for the live
attenuated vaccine. This is in agreement with the previ-
ous studies, showing an increase in antibody titres be-
tween D7 and D21 post-vaccination and a boost of the
immune response following a challenge [16, 17]. Never-
thless, the need of a booster for inactivated vaccines is
usually a constraint compared to live attenuated vaccine
that need only one shot. Thus, it will be interesting, in a
further study, to assess the vaccine protection using a
single vaccination with killed vaccine.
The kinetic of antibody response in vaccinated sheep
showed that inactivated vaccine provide detectable anti-
body levels for more than nine months, suggesting that
an annual booster with this vaccine is enough to main-
tain a good protection at the population level. The long
term duration of the protection needs to be confirmed
using a challenge experiment. The findings of the
present study are in agreement with other studies, dem-
onstrating the efficacy of the inactivated SPP vaccines to
protect sheep against challenge [17, 18].
The challenge was conducted according to the protocol
defined by Fassi-Fehri and co-workers [11]. This method
allows quantitative assessment of the conferred immunity
and it is based on the obtained titres of the challenge virus
in vaccinated and control animals. The difference of 2 log
titers is used to determine the protection threshold. The
method provides a protection index that is high as the im-
mune response is strong and durable. Despite the high ti-
tres of the virulent challenge virus, both inactivated and
live SPPV vaccines protected experimental animals against
generalization of the disease observed in unvaccinated
sheep. A short increase in body temperature in both vacci-
nated groups was observed for two days, which can be a
physiological response triggered by any antigen. In
contrast, unvaccinated sheep exhibited characteristic
Fig. 3 Temperature monitoring of unvaccinated and vaccinated (G1
and G2) sheep during 14 days post-challenge
10-1 10-2 10-3 10-4 10-5 10-6
10-1 10-2 10-3 10-4 10-5 10-6
BA
Fig. 4 a Figure of challenged unvaccinated sheep showing local inflammations on site of inouclation (flank) with 10–1 to 10–6 dilutions (left to right)
of virulent SPPV in five replica. b Challenged vaccinated sheep showing no local inflammations on the injection sites
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clinical signs, primary and secondary pox lesions with high
fever between D4 and D11 post-infection with the chal-
lenge virus. The obtained virus titre in unvaccinated
control animals reached 105.7ID50/mlwhich is the normal
titre of the virulent strain in sheep.
Inflammation due to the virus replication was ob-
served only in low dilutions for both groups with
lower infectious titres if compared to control animals,
giving evidence of the virulent virus neutralization by the
conferred immunity. There was no significant difference
between live and inactivated vaccines after the challenge as
indicated by the protection index values (4.6 versus 4.0).
These values are comparable to those normally obtained
with other live vaccines [19] and are in compliance with the
OIE procedure of testing the vaccine potency taking a dif-
ference of log10 titre > 2.5 as evidence of protection [20].
Conclusion
There are only limited studies on inactivated SPP
vaccines and very few reports comparing the efficacy
of live and attenuated vaccines [17, 18]. The current
study showed that the developed inactivated Roma-
nian SPPV vaccine is as potent as live vaccine and
has a potential to replace attenuated vaccine to con-
trol and prevent sheep pox in disease-free or endemic
countries, especially in those countries where the use
of live vaccine is unauthorized. Inactivated vaccine is
completely safe in all animals, does not present any
risk of diffusion, reversion or extraneous pathogens
spread.
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Table 1 Challenge results in control and vaccinated sheep with live and inactivated Romanian SPPV vaccine. Antibody neutralizing
titers of vaccinated sheep obtained before challenge. The infectious titer represents the maximum value obtained between day 6
and 8 post challenge





















Control animals 299 0 0 0 0 5.2 5,4(a) 0 0(a)
277 0 0 5.6 0
Live SPPV vaccine 977 1,6 1,6 1,9 1,7 1,5 0,75(b) 3,9 4,6(b)
928 1,6 1,26 0,5 4,9
934 1,4 1,98 0,5 4,9
999 1,8 1,5 0,5 4,9
Inactivated SPPV
vaccine
948 2,7 2,2 1,98 2,2 2,1 1,4 (b) 3,3 4 (b)
941 0 2,22 2,5 2,9
949 4,5 2,46 0,5 4,9
397 1,1 1,98 0,5 4,9
398 2,5 2,46 0,5 4,9
998 0,9 1,74 0,5 4,9
973 4,5 2,46 0,5 4,9
969 1,5 2,7 4,1 1,3
(a–b) indicate a significant difference in means of infectious titers and protection values between vaccinated and unvaccinated animals and between G1 and G2
at the 0.05 level
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